Health-related quality of life with standard and curative therapies in thalassemia: A narrative literature review

被引:4
作者
Shah, Richa [1 ]
Badawy, Sherif M. [2 ,3 ,4 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med Educ, Chicago, IL USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA
[3] Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol & Stem Cell Transplant, Chicago, IL 60611 USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, 225 E Chicago Ave,Box 30, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
gene therapy editing; luspatercept; patient-reported outcomes; quality of life; stem cell transplant; thalassemia; STEM-CELL TRANSPLANTATION; PATIENT-REPORTED OUTCOMES; TRANSFUSION-DEPENDENT THALASSEMIA; BONE-MARROW-TRANSPLANTATION; BETA-THALASSEMIA; CHELATION-THERAPY; EQUIVALENCE; DISEASE; IMPACT; SF-36;
D O I
10.1111/nyas.15100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Health-related quality of life (HRQOL) is a patient-reported outcome that assesses the impact of a disease or illness on different domains of a patient's life. Different general and disease-specific measures can be used to evaluate HRQOL. This article aimed to summarize the evidence for HRQOL among patients with transfusion-dependent (TDT) and non-transfusion-dependent thalassemia (NTDT). We included HRQOL data related to standard therapy with blood transfusions, iron chelation, and/or luspatercept in TDT and NTDT, as well as curative therapies for TDT, including hematopoietic stem cell transplant (HSCT) and gene therapy. Patients with thalassemia had worse HRQOL scores compared to the general population, and chronic pain was seen to increase in frequency and severity over time with age. NTDT patients reported worse physical health and functioning, mental health, general health, and vitality than TDT patients. However, TDT patients reported worse pain, change in health, and social support than NTDT. Most therapies improved overall HRQOL among thalassemia patients. Deferasirox, an oral iron chelator, was associated with more HRQOL benefits compared to deferoxamine, an intravenous iron chelator. Luspatercept showed clinically meaningful improvement in physical functioning among TDT and NTDT. Furthermore, HSCT and gene therapy were associated with better physical, emotional, and mental domains scores. Health-related quality of life (HRQOL) is a patient-reported outcome that assesses the impact of a disease on different domains of a patient's life. This article summarizes the HRQOL among patients with transfusion-dependent (TDT) and non-transfusion-dependent thalassemia (NTDT). Patients with thalassemia had worse HRQOL scores compared to the general population. NTDT patients reported worse physical, mental, and general health than TDT patients. Most therapies improved overall HRQOL among thalassemia patients.image
引用
收藏
页码:50 / 62
页数:13
相关论文
共 72 条
[1]  
Abbasi Samira, 2020, Int J Hematol Oncol Stem Cell Res, V14, P19
[2]   Quality of life outcomes in thalassaemia patients in Saudi Arabia: a cross-sectional study [J].
Adam, Soheir .
EASTERN MEDITERRANEAN HEALTH JOURNAL, 2019, 25 (12) :887-895
[3]   Prevalence of Transfusion Transmitted: Infections and the Quality of Life in β-thalassemia Major Patients [J].
Al-Moshary, May ;
Al-Mussaed, Eman ;
Khan, Adnan .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (11)
[4]   Health-related quality of life (HRQoL) in beta-thalassemia major (β-TM) patients assessed by 36-item short form health survey (SF-36): a meta-analysis [J].
Arian, Mahdieh ;
Mirmohammadkhani, Majid ;
Ghorbani, Raheb ;
Soleimani, Mohsen .
QUALITY OF LIFE RESEARCH, 2019, 28 (02) :321-334
[5]   Validation of the SF-36 in Jamaicans with sickle-cell disease [J].
Asnani, Monika R. ;
Lipps, Garth E. ;
Reid, Marvin E. .
PSYCHOLOGY HEALTH & MEDICINE, 2009, 14 (05) :606-618
[6]   Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework [J].
Badawy, Sherif M. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2021, (01) :196-205
[7]   A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy [J].
Badawy, Sherif M. ;
Beg, Usman ;
Liem, Robert, I ;
Chaudhury, Sonali ;
Thompson, Alexis A. .
BLOOD ADVANCES, 2021, 5 (02) :570-583
[8]  
Badawy SM., 2016, NONMALIGNANT HEMATOL, P39
[9]   An Epidemiological Study of the Quality of Life of Children With Beta-Thalassemia Major (?-TM) and Its Correlates in Kolkata, West Bengal, India [J].
Biswas, Bijit ;
Naskar, Narendra N. ;
Basu, Keya ;
Dasgupta, Aparajita ;
Basu, Rivu ;
Paul, Bobby .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
[10]   Transfusion-transmitted infections, its risk factors and impact on quality of life: An epidemiological study among β-thalassemia major children [J].
Biswas, Bijit ;
Naskar, Narendra ;
Basu, Keya ;
Dasgupta, Aparajita ;
Basu, Rivu ;
Paul, Bobby .
ASIAN JOURNAL OF TRANSFUSION SCIENCE, 2022, 16 (01) :99-105